Recorded fact · drug.trial_access

drug.trial_access for ustekinumab

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact cb28fcda resolves to.

The record

Fact id	`cb28fcdaa01602b827998f24`
Entity	drug: ustekinumab
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "USTEKINUMAB",
 "recruitingInterventionalCount": 17,
 "notYetRecruitingCount": 6,
 "byPhase": {
  "PHASE4": 7,
  "PHASE1/PHASE2": 1,
  "PHASE3": 2,
  "PHASE2": 4,
  "NA": 2,
  "PHASE1": 1
 },
 "trials": [
  {
   "nctId": "NCT07310095",
   "briefTitle": "A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Xian-Janssen Pharmaceutical Ltd.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2025-12-30",
   "conditions": [
    "Crohn Disease"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07310095"
  },
  {
   "nctId": "NCT03167437",
   "briefTitle": "An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2017-10-30",
   "conditions": [
    "Crohn's Disease"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03167437"
  },
  {
   "nctId": "NCT07116967",
   "briefTitle": "Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Bristol-Myers Squibb",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-28",
   "startDate": "2025-09-22",
   "conditions": [
    "Plaque Psoriasis"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Belgium",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07116967"
  },
  {
   "nctId": "NCT05928039",
   "briefTitle": "PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "University of Calgary",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-26",
   "startDate": "2023-10-25",
   "conditions": [
    "Crohn Disease"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05928039"
  },
  {
   "nctId": "NCT06807593",
   "briefTitle": "Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "M.D. Anderson Cancer Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-14",
   "startDate": "2026-02-24",
   "conditions": [
    "Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06807593"
  },
  {
   "nctId": "NCT06274554",
   "briefTitle": "Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Weill Medical College of Cornell University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-08-20",
   "startDate": "2024-10-04",
   "conditions": [
    "Crohn's Disease",
    "Inflammatory Bowel Diseases"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06274554"
  },
  {
   "nctId": "NCT07138898",
   "briefTitle": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "NYU Langone Health",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-07-09",
   "startDate": "2025-12-12",
   "conditions": [
    "Rheumatic Disease"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07138898"
  },
  {
   "nctId": "NCT07529236",
   "briefTitle": "Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis,",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Centre Hospitalier Universitaire de Nice",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-06-25",
   "startDate": "2026-04-20",
   "conditions": [
    "Chronic Inflammatory Bowel Diseases"
   ],
   "countries": [
    "France"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07529236"
  },
  {
   "nctId": "NCT05327790",
   "briefTitle": "LFMT vs Placebo in New Biologic Start for Ulcerative Colitis",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "University of Alberta",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-05-06",
   "startDate": "2022-06-03",
   "conditions": [
    "Ulcerative Colitis"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05327790"
  },
  {
   "nctId": "NCT05169593",
   "briefTitle": "Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Universitaire Ziekenhuizen KU Leuven",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-05-05",
   "startDate": "2022-09-08",
   "conditions": [
    "Crohn Disease"
   ],
   "countries": [
    "Belgium",
    "Italy"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05169593"
  },
  {
   "nctId": "NCT05270733",
   "briefTitle": "Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "University Hospitals Cleveland Medical Center",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-04-02",
   "startDate": "2022-11-10",
   "conditions": [
    "Psoriasis"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05270733"
  },
  {
   "nctId": "NCT06520397",
   "briefTitle": "Efficacy and S
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 2f834487ab0037eedc31d5a035ea2cc7048d3bc1fd4f03d1f2cf00983357cc4a.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.